A phosphodiesterase-4 inhibitor reduces lung inflammation and fibrosis in a hamster model of SARS-CoV-2 infection (original) (raw)
Differential expression of cyclic nucleotide phosphodiesterases 4 in developing rat lung
EMMANUEL JESUS JIMENEZ LOPEZ
Developmental Dynamics, 2010
View PDFchevron_right
Role of Phosphodiesterases in Biology and Pathology 2.0
Mara Massimi
International journal of molecular sciences, 2024
View PDFchevron_right
Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?
Mara Massimi
International Journal of Molecular Sciences
View PDFchevron_right
Identification of SARS-CoV-2 inhibitors using lung and colonic organoids
xiaohua duan
Nature, 2020
View PDFchevron_right
Using in vivo animal models for studying SARS-CoV-2
Norman A Ratcliffe
Expert Opinion on Drug Discovery, 2021
View PDFchevron_right
COVID-19 and phosphodiesterase enzyme type 5 inhibitors
Ali Al-Gareeb
Journal of Microscopy and Ultrastructure, 2020
View PDFchevron_right
A phosphodiesterase 4 inhibitor, roflumilast N-oxide, inhibits human lung fibroblast functions in vitro
Loredana Petecchia
Pulmonary Pharmacology & Therapeutics, 2010
View PDFchevron_right
Synthesis, docking, characterization and anti-inflammatory activity of novel phosphodiesterase-4 inhibitors
shikha raheja
Asian Journal of Pharmacy and Pharmacology, 2018
View PDFchevron_right
Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
theodore sala
Frontiers in Oncology, 2020
View PDFchevron_right
Current targets and drug candidates for prevention and treatment of SARS-CoV-2 (COVID-19) infection
Rajiv Tonk
Reviews in Cardiovascular Medicine, 2020
View PDFchevron_right
Discovering small-molecule therapeutics against SARS-CoV-2
Vaibhav Tiwari
Drug Discovery Today, 2020
View PDFchevron_right
Phosphodiesterase Inhibitors: Their role and implications
Rumi Ghosh
International Journal of …, 2009
View PDFchevron_right
Predicted therapeutic targets for COVID-19 disease by inhibiting SARS-CoV-2 and its related receptors
Niloofar Mohammadi
Informatics in Medicine Unlocked, 2020
View PDFchevron_right
Role of phosphodiesterase 1 in the pathophysiology of diseases and potential therapeutic opportunities
Sakthivel Muniyan
Pharmacology & Therapeutics, 2021
View PDFchevron_right
Interaction between SARS-CoV-2 and human organism
Valentin Cebotarescu
2020
View PDFchevron_right
Bronchiolitis and SARS-CoV-2
Anna Luganini
Archives of Disease in Childhood, 2021
View PDFchevron_right
Phosphodiesterase (PDE)-4 Inhibitors and COPD Correlation with Cancer
Sofia Lampaki
Journal of Cancer, 2014
View PDFchevron_right
Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future
Mauro Martins
Trends in Pharmacological Sciences, 1997
View PDFchevron_right
Inhibition of phosphodiesterase 4 modulates cytokine induction from toll like receptor activated, but not rhinovirus infected, primary human airway smooth muscle
Lucy Morgan
Respiratory Research, 2013
View PDFchevron_right
Biological Mechanisms of COVID-19 Acute Respiratory Distress Syndrome
Aleksandra Leligdowicz
American Journal of Respiratory and Critical Care Medicine, 2020
View PDFchevron_right
Commentary: Effect of Angiotensin-Converting-Enzyme Inhibitor and Angiotensin II Receptor Antagonist Treatment on ACE2 Expression and SARS-CoV-2 Replication in Primary Airway Epithelial Cells
Fedor Simko
Frontiers in Pharmacology, 2022
View PDFchevron_right
Therapeutic potential of a new phosphodiesterase inhibitor in acute lung injury
Lidia Lima
European Respiratory Journal, 2003
View PDFchevron_right
Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19
Gaurav Joshi
Cellular Signalling, 2020
View PDFchevron_right
SARS-CoV-2 infection triggers pro-atherogenic inflammatory responses in human coronary vessels
Natalia Eberhardt
Nature Cardiovascular Research, 2023
View PDFchevron_right
Pathophysiology and Potential Therapeutic Candidates for COVID-19: A Poorly Understood Arena
vijaya nag
2020
View PDFchevron_right
Phosphodiesterase Type 4 Inhibitors Cause Proinflammatory Effects in Vivo
Kerryn McCluskie
Journal of Pharmacology and Experimental Therapeutics, 2006
View PDFchevron_right
PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking
hayder M Al-kuraishy
Review, 2021
View PDFchevron_right
Immunopathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a concise update
Hardyanto Soebono
Journal of thee Medical Sciences (Berkala Ilmu Kedokteran)
View PDFchevron_right
SARS-CoV-2 Systemic Effects: New Clues
daria bortolotti
Microorganisms, 2023
View PDFchevron_right
SARS-CoV-2 infection triggers pro-atherogenic inflammatory 1 responses in human coronary vessels
Natalia Eberhardt
bioRxiv (Cold Spring Harbor Laboratory), 2023
View PDFchevron_right
Phosphodiesterase-4 in Atopic dermatitis, systematic review
hassan mohammed
Fayoum University Medical Journal, 2021
View PDFchevron_right
COVID-19 and SARS-CoV-2: Despite the vaccination, new targets/drugs for treatment and the virus cycle mechanisms still have to be continually investigated
Marcia Rodrigues Amorim
Open Journal of Proteomics and Genomics, 2021
View PDFchevron_right
Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: targeting a potential IL-1β/Neutrophil Extracellular Traps feedback loop
Ahmed Yaqinuddin
Medical Hypotheses, 2020
View PDFchevron_right
A new way to fight sars-cov-19
Valentyn Nastasenko
Materials Science and Nanotechnology, 2021
View PDFchevron_right
Double-blind, Randomized, Placebo-controlled Trial With N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by Coronavirus Disease 2019 (COVID-19)
ELIZABETH APARECIDA DA SILVA
Clinical Infectious Diseases, 2021
View PDFchevron_right